RAPT Therapeutics, Inc. (RAPT) Capital Expenditures (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Capital Expenditures for 5 consecutive years, with $1000.0 as the latest value for Q4 2024.
- Quarterly Capital Expenditures fell 98.51% to $1000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $122000.0 through Dec 2024, down 89.16% year-over-year, with the annual reading at $122000.0 for FY2024, 89.16% down from the prior year.
- Capital Expenditures hit $1000.0 in Q4 2024 for RAPT Therapeutics, down from $17000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $759000.0 in Q1 2023 to a low of -$1000.0 in Q2 2024.
- Historically, Capital Expenditures has averaged $170789.5 across 5 years, with a median of $98000.0 in 2020.
- Biggest five-year swings in Capital Expenditures: surged 784.38% in 2022 and later crashed 100.43% in 2024.
- Year by year, Capital Expenditures stood at $174000.0 in 2020, then soared by 126.44% to $394000.0 in 2021, then plummeted by 87.56% to $49000.0 in 2022, then surged by 36.73% to $67000.0 in 2023, then plummeted by 98.51% to $1000.0 in 2024.
- Business Quant data shows Capital Expenditures for RAPT at $1000.0 in Q4 2024, $17000.0 in Q3 2024, and -$1000.0 in Q2 2024.